Broad-spectrum coverage for a broad range of cIAI patients1
Empirically treat complicated intra-abdominal infection (cIAI) in adults with XERAVA
Explore XERAVA
Why XERAVA
Powerful empiric treatment for
more of your cIAI patients 2
Broad-spectrum activity that covers Gram-positive, Gram-negative, and anaerobic bacteria, including multidrug-resistant strains1
Proven clinically effective vs. carbapenem therapy; effective and safe as a monotherapy3
Optimal dosing with 5+ years
of real‑world experience and requires no renal dose adjustments or therapeutic drug monitoring4
Efficacy
Confidently
take on cIAI
In 2 rigorous phase 3, randomized, double-blind, double-dummy, multicenter, prospective trials comparing XERAVA with either ertapenem or meropenem for patients with cIAI, XERAVA demonstrated3,5:
- Robust efficacy as monotherapy3,5,6
- High clinical cure rates
- Success against resistant strains
Safety
Well tolerated in 2 pivotal
clinical trials
Safety was evaluated in 2 pivotal trials that included a broad range of patients.
Learn more about safetyWant to
know more?
Request to speak with a
XERAVA sales representative
or receive information.
Lead the
charge
Choose broad-spectrum
coverage for a broad range of
cIAI patients with XERAVA.1
References:
- Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76(5):567-588. doi: 10.1007/s40265-016-0545-8.
- Sartelli M, Coccolini F, Kluger Y, et al. WSES/GAIS/
SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infections. World J Emerg Surg. 2021;16(49):1-48. doi: 10.1186/ s13017‑021-00387-8. - Solomkin JS, Gardovskis J, Lawrence K, et al. IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections. Clin Infect Dis. 2019;69(6):921-929. doi: 10.1093/cid/
ciy1029. - Kunz Coyne AJ, Alosaimy S, Lucas K, et al. Eravacycline, the first four years: health outcomes and tolerability for 19 hospitals in 5 U.S. regions from 2018 to 2022. Microbiol Spectr. 2024;12(1):1-14. doi: 10.1128/
spectrum.02351-23. - Solomkin J, Evans D, Slepavicius A, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg. 2017;152(3):224-232. doi: 10.1001/
jamasurg.2016.4237. - Grant-Di Felice V, Efimova E, Izmailyan S, et al. Efficacy and tolerability of eravacycline in bacteremic patients with complicated intra-abdominal infection: a pooled analysis from the IGNITE1 and IGNITE4 studies. Surg Infect. 2021:22(5):556-561. doi: 10.1089/sur.2020.241.
- Ditch K, Newman J, Izmailyan S, et al. Microbiological efficacy of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including MDR isolates: a pooled analysis from IGNITE1 and IGNITE4, two phase 3 trials of complicated intra-abdominal infection. Poster presented at: ASM Microbe; June 7-11, 2018; Atlanta, GA. Poster P629.
- Magiorakos AP, Srinivasan A, Carey RB, et al. Multi-drug resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-281. doi: 10.1111/
j.1469‑0691.2011.03570.x.
Indications & Usage
Indications
XERAVA® (eravacycline) for injection is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens, Bacteroides species, and Parabacteroides distasonis in patients 18 years or older.
Limitations of Use XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI).
Usage
To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Important Safety Information
XERAVA is contraindicated for use in patients with known hypersensitivity to eravacycline, tetracycline-class antibacterial drugs, or to any of the excipients. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with XERAVA.
The use of XERAVA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.
The use of XERAVA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth.
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis.
The most common adverse reactions observed in clinical trials (incidence ≥3%) were infusion site reactions (7.7%), nausea (6.5%), and vomiting (3.7%).
XERAVA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri, and anti-anabolic action which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with XERAVA. Discontinue XERAVA if any of these adverse reactions are suspected.
You are encouraged to report negative side effects of prescription drugs to the FDA. To report SUSPECTED ADVERSE REACTIONS, please contact:
Innoviva Specialty Therapeutics, Inc.™
1‑800‑651‑3861
U.S. Food and Drug Administration
1‑800‑FDA‑1088
Before administering, please see the Full Prescribing Information for XERAVA.